<DOC>
	<DOCNO>NCT00217581</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , oxaliplatin docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab together oxaliplatin docetaxel may kill tumor cell . PURPOSE : This phase II trial study well give bevacizumab together oxaliplatin docetaxel work treat patient locally advance unresectable metastatic stomach gastroesophageal junction cancer .</brief_summary>
	<brief_title>Bevacizumab , Oxaliplatin , Docetaxel Treating Patients With Locally Advanced Unresectable Metastatic Stomach Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression patient locally advance unresectable metastatic gastric gastroesophageal junction adenocarcinoma treat bevacizumab , oxaliplatin , docetaxel . Secondary - Determine response rate patient treat regimen . - Determine toxic effect regimen patient . - Determine time treatment failure overall survival patient treat regimen . - Determine change general disease-specific quality life , term response treatment , patient treat regimen . OUTLINE : This multicenter study . Patients receive bevacizumab IV 30-90 minute , oxaliplatin IV 120 minute , docetaxel IV 60 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 38 patient accrue study within 18-23 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm gastric gastroesophageal junction adenocarcinoma Locally advance unresectable metastatic disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10mm spiral CT scan Bone metastasis , ascites , pleural effusion consider measurable disease Evaluable disease must present outside previously irradiate field No CNS brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status SWOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 mg/dL No evidence bleed diathesis coagulopathy Hepatic AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ ULN INR &lt; 1.5 Renal Creatinine &lt; 2.0 mg/dL Urine protein : creatinine ratio &lt; 1.0 Cardiovascular No history deep venous thrombosis require anticoagulation No active angina No myocardial infarction within past year No cerebrovascular accident within past year No uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 170 mm Hg and/or diastolic BP &gt; 100 mm Hg ) despite medical management Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No peripheral neuropathy &gt; grade 1 No history allergy study drug drug formulate polysorbate 80 No know HIV infection No active peptic ulcer disease No serious nonhealing wound , ulcer , bone fracture No unresolved bacterial infection require antibiotic No active malignancy within past 3 year except cancer treat curative intent PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy gastric cancer unless disease relapse &gt; 6 month completion nontaxane adjuvant chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 3 week since radiotherapy Surgery At least 4 week since prior surgery open biopsy ( except indwell venous catheter placement ) No concurrent surgery Other At least 4 week since prior concurrent participation another experimental drug trial No concurrent fulldose anticoagulation No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>